Phase III Study of Palbociclib in Combination With Exemestane or Fulvestrant vs. Chemotherapy (Capecitabine) in Hormonal Receptor Positive/HER2 Negative Metastatic Breast Cancer Patients With Resistance to Aromatase Inhibitors
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Exemestane (Primary) ; Fulvestrant (Primary) ; Palbociclib (Primary) ; Capecitabine
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PEARL
- 09 Dec 2023 Results assessing Body Mass Index and Treatment Efficacy in advanced Luminal Breast Cancer presented at the 46th Annual San Antonio Breast Cancer Symposium
- 06 Jun 2023 Results investigating the prognostic and predictive value of cytoplasmic and nuclear isoforms of cyclin E in metastatic breast cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 07 Feb 2023 Tumor samples of 455 patients were used for mRNA gene expression profiling and correlation with progression-free-survival (PFS), published in the Clinical Cancer Research